Clinical Data’s Cogenics Division to Provide Global Genotyping Solutions for Lundbeck’s Clinical Studies
2008-07-15 05:30:00
NEWTON, Mass.–(EMWNews)–Clinical Data, Inc. (NASDAQ:CLDA) a leader in the development of
targeted therapeutics and predictive tests from its growing portfolio of
proprietary genetic biomarkers, announced today that its Cogenics®
division has entered into a Scientific Research & Development Agreement
with H. Lundbeck A/S to support its ongoing clinical studies with
genotyping solutions on a global basis. Lundbeck is an international
pharmaceutical company engaged in the research and development,
production, marketing and sale of drugs for the treatment of psychiatric
and neurological disorders.
Under the agreement, Cogenics will employ its clinical genotyping
platforms and expertise based in Morrisville, North Carolina and
Bernried, Germany, to support Lundbeck’s
clinical studies world-wide, initially focusing on Lundbeck’s
Phase I studies. The term of the agreement is open-ended and the parties
intend to collaborate on multiple projects going forward.
“This agreement with Lundbeck underscores
Cogenics’ leading position in the clinical
genotyping field, and we are very pleased to form this partnership,”
says Michael Lutz, Global General Manager of Cogenics. “Having
conducted more than 1700 genotyping studies to support clinical drug
development, we are well positioned to provide value-added genotyping
solutions to Lundbeck on a global basis and in a consistent, high
quality manner.”
For more information about Cogenics and its genomic services offerings,
please call 1-877-226-4364 (U.S.) or +49 (0) 8158 – 99 85-0 (E.U.) or
email [email protected].
About Cogenics
Cogenics, a division of Clinical Data, has established itself as a
leading provider of value-based genomics solutions for both the
Healthcare and Life Sciences industries. These solutions span the areas
of current and next generation sequencing, gene expression, clinical and
non-clinical genotyping, biomanufacturing support and nucleic acid
extraction and biobanking, for both research and regulated environments.
Cogenics combines operations from the acquisitions of Genaissance
Pharmaceuticals, Lark Technologies (in the US and UK), Icoria, Genome
Express (France) and Epidauros Biotechnologie (Germany). Its customers
include some of the world’s most respected
pharmaceutical and biotechnology companies, agencies of the US National
Institutes of Health, leading government and academic researchers in the
international life science community, and major agricultural companies
and agencies. For more information, please visit www.cogenics.com.
About Clinical Data, Inc.
Clinical Data is a global biotechnology company unlocking the potential
of molecular discovery, From Targeted Science to Better Healthcare™.
Its PGxHealth® division focuses on
proprietary biomarker and pharmacogenetic test development as well as
targeted therapeutics to help predict drug safety and efficacy, thereby
reducing health care costs and improving clinical outcomes. Its Cogenics®
division provides genomics services to both research and regulated
environments. Through these divisions, Clinical Data is leveraging
advances in molecular discovery to provide tangible benefits for
patients, doctors, scientists and health plans worldwide. Visit the
company’s website at www.clda.com for
more information.
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of
pharmaceuticals for the treatment of psychiatric and neurological
disorders. In 2007, the company’s revenue was DKK 11 billion
(approximately EUR 1.6 billion or USD 2.0 billion). The number of
employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995
This press release contains certain forward-looking information and
statements that are intended to be covered by the safe harbor for
forward looking statements provided by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that are
not historical facts. Words such as “expect(s)”, “feel(s)”,
“believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are
intended to identify forward-looking statements. These statements
include, but are not limited to, statements about our ability to
successfully integrate the operations, business, technology and
intellectual property obtained in our acquisitions; our ability to
obtain regulatory approval for, and successfully introduce our new
products; our ability to expand our long-term business opportunities;
financial projections and estimates and their underlying assumptions;
and statements regarding future performance. All of such information and
statements are subject to certain risks and uncertainties, the effects
of which are difficult to predict and generally beyond the control of
the Company, that could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include, but
are not limited to, whether Cogenics’
services will gain wide acceptance in the market; competition from
pharmaceutical, biotechnology and diagnostics companies; whether
Clinical Data will be able to develop or acquire additional products and
attract new business and strategic partners; changes in government
regulations, and changing relationships with customers, payers,
suppliers and strategic partners; and those risks identified and
discussed by Clinical Data in its filings with the U.S. Securities and
Exchange Commission. Readers are cautioned not to place undue reliance
on these forward looking statements that speak only as of the date
hereof. Clinical Data does not undertake any obligation to
republish revised forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. Readers are also urged to carefully review and
consider the various disclosures in Clinical Data’s SEC periodic and
interim reports, including but not limited to its Annual Report on Form
10-K for the fiscal year ended March 31, 2008, and Current Reports on
Form 8-K filed from time to time by the Company.
|
EVC Group, Inc. for Clinical Data, Inc. +1-415-896-6817 (investors) Gale, +1-646-201-5431 (media) |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
